COPD treatment choices based on blood eosinophils: Are we there yet?

Oliver, B; Tonga, K; Darley, D; Rutting, S; Zhang, X; Chen, H; Wang, G

COPD treatment choices based on blood eosinophils: Are we there yet?

Oliver, B

Tonga, K Darley, D Rutting, S Zhang, X Chen, H

Wang, G

Permalink

Publication Type:: Journal Article
Citation:: Breathe, 2019, 15 (4), pp. 318 - 323
Issue Date:: 2019-12-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (26.09 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Oliver, B https://orcid.org/0000-0002-7122-9262	en_US
dc.contributor.author	Tonga, K	en_US
dc.contributor.author	Darley, D	en_US
dc.contributor.author	Rutting, S	en_US
dc.contributor.author	Zhang, X	en_US
dc.contributor.author	Chen, H https://orcid.org/0000-0001-6883-3752	en_US
dc.contributor.author	Wang, G	en_US
dc.date.issued	2019-12-01	en_US
dc.identifier.citation	Breathe, 2019, 15 (4), pp. 318 - 323	en_US
dc.identifier.issn	1810-6838	en_US
dc.identifier.uri	http://hdl.handle.net/10453/137489
dc.description.abstract	© ERS 2019. Eosinophils are increasingly being recognised as an important characteristic feature of COPD. Patients with COPD and eosinophilic inflammation tend to respond to steroid therapy; however, many questions remain regarding the optimum measurement. Eosinophilic inflammation may be defined based on various sampling techniques, including eosinophil levels in blood, sputum, bronchoalveolar lavage or biopsy, which leads to inconsistencies in its definition. Blood eosinophils may increase in conjunction with sputum eosinophils during COPD exacerbations and therefore may be a good surrogate marker of airway eosinophilic inflammation. However, the timing of the blood eosinophil measurement, the stability of the eosinophil count and the threshold used in different studies are variable. The use of blood eosinophil count to direct biological therapies in COPD has also had variable outcomes. Eosinophilic inflammation has an important role in COPD management; however, its use as the optimum biomarker still needs further investigation.	en_US
dc.relation.ispartof	Breathe	en_US
dc.relation.isbasedon	10.1183/20734735.0254-2019	en_US
dc.title	COPD treatment choices based on blood eosinophils: Are we there yet?	en_US
dc.type	Journal Article
utslib.citation.volume	4	en_US
utslib.citation.volume	15	en_US
utslib.for	1102 Cardiorespiratory Medicine and Haematology	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.issue	4	en_US
pubs.publication-status	Published	en_US
pubs.volume	15	en_US

Abstract:

© ERS 2019. Eosinophils are increasingly being recognised as an important characteristic feature of COPD. Patients with COPD and eosinophilic inflammation tend to respond to steroid therapy; however, many questions remain regarding the optimum measurement. Eosinophilic inflammation may be defined based on various sampling techniques, including eosinophil levels in blood, sputum, bronchoalveolar lavage or biopsy, which leads to inconsistencies in its definition. Blood eosinophils may increase in conjunction with sputum eosinophils during COPD exacerbations and therefore may be a good surrogate marker of airway eosinophilic inflammation. However, the timing of the blood eosinophil measurement, the stability of the eosinophil count and the threshold used in different studies are variable. The use of blood eosinophil count to direct biological therapies in COPD has also had variable outcomes. Eosinophilic inflammation has an important role in COPD management; however, its use as the optimum biomarker still needs further investigation.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/137489